COVID-19 Total Solution
DiaCarta offers a COVID-19 total solution to support the fight against COVID-19, including the RT-PCR test, antibody IgG test and CLIA lab service.
QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test - Detects 3 genes)
QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test - Detects 1 gene)
QuantiVirus™ Anti-SARS-CoV-2 IgG Test Kit (Antibody Test) - Research Use Only
COVID-19 Clinical Laboratory Testing Service
Our Latest Press Releases for COVID-19 Total Solution
DiaCarta Receives CE/IVD for its New COVID 19 Test that Identifies Delta Plus and New Variants
August 12, 2021 I DiaCarta, Inc.
DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
April 22, 2021 I DiaCarta, Inc.
Press Release
FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests
September 21, 2020 I DiaCarta, Inc.
Press Release
DiaCarta’s COVID-19 Test Ranks Top 10 Among All FDA EUA Tests Based on Limit of Detection
September 2, 2020 I DiaCarta, Inc.
Press Release
DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test
July 15, 2020 I DiaCarta, Inc.
Press Release
DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week
April 13, 2020 I DiaCarta, Inc.
Press Release
DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit
March 25, 2020 I DiaCarta, Inc.